U.S. Markets open in 4 hrs 19 mins
  • S&P Futures

    3,252.75
    -49.50 (-1.50%)
     
  • Dow Futures

    26,161.00
    -396.00 (-1.49%)
     
  • Nasdaq Futures

    11,118.25
    -224.50 (-1.98%)
     
  • Russell 2000 Futures

    1,540.40
    -18.00 (-1.16%)
     
  • Crude Oil

    36.24
    +0.07 (+0.19%)
     
  • Gold

    1,869.90
    +1.90 (+0.10%)
     
  • Silver

    23.35
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1680
    +0.0001 (+0.0117%)
     
  • 10-Yr Bond

    0.8350
    0.0000 (0.00%)
     
  • Vix

    39.66
    -0.62 (-1.54%)
     
  • GBP/USD

    1.2931
    +0.0008 (+0.0621%)
     
  • USD/JPY

    104.3100
    -0.3000 (-0.2868%)
     
  • BTC-USD

    13,213.47
    -160.71 (-1.20%)
     
  • CMC Crypto 200

    258.71
    +16.03 (+6.61%)
     
  • FTSE 100

    5,560.34
    -21.41 (-0.38%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Baudax Bio, Inc.
·4 mins read

MALVERN, Pa., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committee of Baudax Bio’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 24,000 shares of Baudax Bio’s common stock and restricted stock units covering 6,000 shares of Baudax Bio’s common stock to 3 newly-hired employees, with a grant date of September 30, 2020. The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to his or her acceptance of employment with Baudax Bio.

The options have an exercise price equal to $2.77 per share, the closing price of Baudax Bio’s common stock as reported by Nasdaq on September 30, 2020. The options have a ten-year term and vest over four years, with 25% of the number of shares underlying the stock option vesting on the one-year anniversary of the grant date and the remaining shares vesting monthly over 36 months thereafter. The restricted stock units vest annually over four years. The equity awards are subject to each individual’s continued service with Baudax Bio through the applicable vesting dates.

About Baudax Bio, Inc.

Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio’s first commercial product, ANJESO®, began in June of 2020. Baudax’s New Drug Application for ANJESO was approved by the U.S. Food and Drug Administration on February 20, 2020 for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. As a non-opioid, IV meloxicam has the potential to overcome many of the issues associated with commonly prescribed opioid therapeutics, including respiratory depression, constipation, excessive nausea and vomiting, as well as having no addictive potential while maintaining meaningful analgesic effects for relief of pain. For more information please visit www.baudaxbio.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio's expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,” “intend,” and “expect,” and similar expressions, as they relate to Baudax Bio or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Baudax Bio as of the date of publication on this internet site and are subject to a number of risks, uncertainties, and other factors that could cause Baudax Bio’s performance to differ materially from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are subject to risks and uncertainties including, among other things, the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the commercial launch of ANJESO® or disruption in supply chain, Baudax Bio’s ability to maintain regulatory approval for ANJESO, Baudax Bio’s ability to successfully commercialize ANJESO; the acceptance of ANJESO by the medical community, including physicians, patients, health care providers and hospital formularies, Baudax Bio’s ability and that of Baudax Bio’s third party manufacturers to successfully scale-up its commercial manufacturing process for ANJESO, Baudax Bio’s ability to produce commercial supply in quantities and quality sufficient to satisfy market demand for ANJESO, Baudax Bio’s ability to raise future financing for continued product development, payment of milestones and ANJESO commercialization, Baudax Bio’s ability to pay its debt and satisfy conditions necessary to access future tranches of debt, Baudax Bio’s ability to comply with the financial and other covenants under its credit facility, Baudax Bio’s ability to manage costs and execute on its operational and budget plans, the accuracy of Baudax Bio’s estimates of the potential market for ANJESO, Baudax Bio’s ability to achieve its financial goals; and Baudax Bio’s ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection. These forward-looking statements should be considered together with the risks and uncertainties that may affect Baudax Bio’s business and future results included in its filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assume no obligation to update any forward-looking statements except as required by applicable law.

CONTACT:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
sam@argotpartners.com
claudia@argotpartners.com

Baudax Bio, Inc.
Ryan D. Lake
(484) 395-2436
rlake@baudaxbio.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com